Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor)
called pazopanib which is being studied in kidney cancer will be combined with standard
chemotherapy called taxol in patients with relapsed recurrent urothelial cancer.